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Using a rapid screening method, we investigated the
prevalence in fecal carriage of antimicrobial drug–resistant
Escherichia coli in 3,174 healthy children from 4 urban set-
tings in Peru and Bolivia. High resistance rates were
observed for ampicillin (95%), trimethoprim-sulfamethoxa-
zole (94%), tetracycline (93%), streptomycin (82%), and
chloramphenicol (70%). Lower resistance rates were
observed for nalidixic acid (35%), kanamycin (28%), gen-
tamicin (21%), and ciprofloxacin (18%); resistance to ceftri-
axone and amikacin was uncommon (<0.5%). In a random
sample of 1,080 resistant E. coli isolates, 90% exhibited a
multidrug-resistance (MDR) phenotype. The 2 most com-
mon MDR phenotypes (ampicillin/tetracycline/trimetho-
prim-sulfamethoxazole and ampicillin/tetracycline/ tri-
methoprim-sulfamethoxazole/chloramphenicol) could be
transferred en bloc in conjugation experiments. The most
common acquired resistance genes were blaTEM,  tet(A),
tet(B), drfA8, sul1, sul2, and catI. These findings under-
score the magnitude of the problem of antimicrobial drug
resistance in low-resource settings and the urgent need for
surveillance and control of this phenomenon.
T
he spread of microbial drug resistance is a global pub-
lic health challenge, which impairs the efficacy of
antimicrobial agents and results in substantial increased
illness and death rates and healthcare-associated costs
(1–3). In low-resource countries, the extent and the impact
of the phenomenon tend to be even larger than in industri-
alized countries. In fact, high resistance rates have often
been reported in surveillance studies dealing with clinical
isolates (1,4,5) and in prevalence studies of commensal
bacteria taken as indicators to estimate spread of acquired
resistance (6–15). Moreover, in low-resource countries the
impact of antimicrobial drug resistance on illness and
death rates tends to be greater because of the high preva-
lence of bacterial infections and the major role of antimi-
crobial agents in combating infectious diseases
(1,3,4,16,17). The high antimicrobial drug resistance rates
observed in low-resource countries are likely due to a com-
bination of several factors, among which irrational antimi-
crobial drug usage and conditions of poor sanitation are
thought to play a major role, even if the relative impor-
tance of additional factors remains unclear (1,4,8,9).
ANTRES (Towards Controlling Antimicrobial Use and
Resistance in Low-Income Countries: An intervention
Study in Latin America) is a research project that aims to
investigate this phenomenon on a large scale. The project is
carried out in 2 Latin American countries, Bolivia and Peru,
where 4 urban areas have been selected for studying antimi-
crobial drug use and bacterial resistance in healthy children
by a prospective approach. An information-education-com-
munication strategy will be developed based on the collect-
ed information and involving local health services. The
impact on antimicrobial drug use and bacterial resistance
trends will be evaluated (http://www.unifi.it/infdis/antres/
default.htm).
We report the results of the baseline study, carried out
at the beginning of the project, to assess the antimicrobial
drug resistance rates in the studied areas. Very high
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Materials and Methods
Study Design and Population
The study population was represented by healthy chil-
dren 6–72 months of age from 4 urban areas, 2 in Bolivia
(Camiri, Santa Cruz Department; Villa Montes, Tarija
Department) and 2 in Peru (Yurimaguas, Loreto
Department; Moyobamba, San Martin Department). The
urban areas were communities of ≈25,000 to 30,000 inhab-
itants who had comparable demographic and socioeco-
nomic characteristics. Eight hundred children from each
area were enrolled in the study to cover at least 25% of all
households with children in the target age cohort. Only
children who had not had diarrhea (as defined by the World
Health Organization [18]) during the previous 24 hours
were eligible for inclusion in the study. In each household,
the youngest recruitable child in the target age cohort was
selected. The studied households were selected with a
modified cluster sampling: detailed maps outlining the dis-
tribution of households were obtained from each study
area, and each city was divided into 80 small clusters. In
each cluster a number of households selected at random
were visited until 10 children were reached. A rectal swab
was obtained from each child enrolled in the study, after
informed consent was obtained from parents or other legal
guardians. Before the sample was obtained, adult members
of the household were interviewed to collect information
on the family’s socioeconomic and cultural setting, the
household antimicrobial drug use, and the health status of
the selected child. In each country, full ethical clearance
was obtained from the qualified authorities who had
revised and approved the study design.
The overall acceptance rate was >95% in all studied
areas. Rectal swabs were obtained from a total of 3,174
children (Figure 1): 794 from Camiri and 790 from Villa
Montes, Bolivia; 797 from Yurimaguas, and 793 from
Moyobamba, Peru. The study participants were 6–72
months of age (mean 34.7 ± 18.2 months; median age 33.5
months).The female:male ratio was 0.95. No significant
differences in age or sex were observed among children
enrolled from the different areas. The study was carried out
for 4 months (August–November 2002). In each area, the
sampling period was not longer than 7 weeks.
Screening for Resistant Escherichia coli in
Commensal Microbiota 
Rectal swabs, stored in Amies transport medium
(Oxoid, Milan, Italy), were transferred in a cold box to the
laboratory of the corresponding district hospital within 3
hours of collection. The 4 laboratories participate in
national quality control programs. A training phase and a
pilot study preceded the survey. Three European investiga-
tors (AB, MB, LP) participated in the sample analysis in
the 4 laboratories. This approach was chosen to limit vari-
ability in the microbiologic procedures during the field
studies. 
Screening for antimicrobial-resistant E. coli in the fecal
microbiota was carried out by a direct plating method, as
described previously (7,19). This method is preferred
because it correlates well with methods based on testing of
randomly collected colonies from primary stool culture,
but it is more sensitive (11,19). 
Briefly, each swab was spread on a McConkey agar no.
3 plate (Oxoid) to yield uniform growth, and antimicrobial
drug–containing disks were directly placed onto the seed-
ed plate. Antimicrobial agents tested included ampicillin,
ceftriaxone, tetracycline, trimethoprim-sulfamethoxazole,
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Figure 1. Flow chart of microbiologic analysis of fecal samples.
DPM, direct plating method.chloramphenicol, streptomycin, kanamycin, gentamicin,
amikacin, nalidixic acid, and ciprofloxacin (Oxoid). After
incubation at 37°C for 12 to 14 hours, plates were inspect-
ed for growth, and inhibition zone diameters were meas-
ured. The presence of a growth inhibition zone larger than
the established breakpoint diameter was considered to
indicate susceptibility to that agent. The presence of a
growth inhibition zone smaller than the breakpoint diame-
ter, the absence of any inhibition zone, or the presence of
isolated colonies growing inside an inhibition zone of any
size was considered indicative of resistance. In the latter
case, however, resistance was considered not to be repre-
sented in the dominant flora. Breakpoints were as previ-
ously described for ampicillin, tetracycline, trimethoprim-
sulfamethoxazole, chloramphenicol, amikacin, nalidixic
acid, and ciprofloxacin (19), and 14 mm, 12 mm, 12 mm,
and 14 mm for kanamycin, streptomycin, gentamicin, and
ceftriaxone, respectively (A. Bartoloni, unpub. data). Only
bacterial growth exhibiting a shape typical of E. coli was
considered valid for the analysis. Specially prepared forms
were used to record microbiologic results, including
growth features and susceptibility patterns. Confluent bac-
terial growth was obtained from 3,130 (99%) of the 3,174
collected rectal swabs (Figure 1). In a few cases insuffi-
cient growth (11 swabs) or noncoliform growth (33 swabs)
was observed. From each plate and for each drug, the puta-
tively resistant coliform growth (i.e., a pool of the colonies
grown inside the zone of inhibition or a loopful of the
microbial lawn grown in proximity of the disk) were col-
lected (n = 18,042) (Figure 1). Of these, a random sample
(10%–25% for each drug, depending on the prevalence of
the resistance phenotype) were subjected to confirmatory
analysis for resistant E. coli (Figure 1) by using the
API20E identification system (bioMérieux, Marcy l’É-
toile, France) and the standard agar disk diffusion method
(20,21). Confirmation was obtained in >96% of the
tested samples, without significant differences among the
4 laboratories. 
Analysis of Resistance Patterns of Commensal E. coli
Susceptibility to several antimicrobial agents represen-
tative of various classes (ampicillin, tetracycline, trimetho-
prim-sulfamethoxazole, chloramphenicol, kanamycin,
gentamicin, nalidixic acid, ciprofloxacin) was tested in
1,405 (8%) E. coli isolates randomly selected from the
18,042 collected samples. Each isolate was spread onto
Mueller-Hinton (MH) agar plates containing each antimi-
crobial agent at a concentration 20% higher than the break-
points for resistance of each antimicrobial agent, as per
National Committee of Laboratory Standards guidelines
(20,21). The inoculum size was ≈2 × 105 CFU per spot. A
plate of antimicrobial drug–free medium was always
included as a growth control. E. coli ATCC 25922, and E.
coli strains from our collection resistant to the various
antimicrobial agents used in the assay were always includ-
ed for quality control purposes. Results were recorded
after incubation at 37°C for 18 hours. A resistance pheno-
type was assigned when growth was observed on the medi-
um containing an antimicrobial agent. An MDR phenotype
was intended as resistance to >2 classes of antimicrobial
agents. Isolates from the same study participant that exhib-
ited the same resistance phenotype (the random sampling
procedure did not initially consider the study participant
source) were considered replicated isolates and were
counted only once for data analysis. According to this cri-
terion, data analysis was conducted with 1,080 isolates
(Figure 1). 
Data entry and analysis were calculated with the
EpiInfo software package (version 2002, Centers for
Disease Control and Prevention, Atlanta, GA, USA).
Statistical differences in the prevalence of antimicrobial
drug resistances were determined by the χ2 test.
Molecular Analysis of Resistance Genes and
Conjugation Assay
Acquired resistance genes and conjugative transfer of
resistance traits were investigated in 78 isolates randomly
selected from those representative of the 2 most common
MDR phenotypes (Figure 1). Resistance genes blaTEM,
catI, dfrA8, sul1, and sul2 and the intI1 integrase gene
were detected by colony blot hybridization (22) with spe-
cific probes generated by polymerase chain reaction
(PCR), as described previously (23–25). Tetracycline
resistance genes tet(A),  tet(B),  tet(C), and tet(D) were
detected by PCR, as described previously (26).
Conjugative transfer of resistance genes was assayed in
MH broth using E. coli J53 (auxotropic for proline and
methionine and resistant to rifampin and nalidixic acid) as
a recipient and an initial donor/recipient ratio of 0.1.
Mating tubes were incubated at 30°C for 14 h.
Transconjugants were selected on MH agar containing
rifampin (400 µg/mL) and nalidixic acid (32 µg/mL) plus
one of the following antimicrobial agents: ampicillin (200
µg/mL), tetracycline (5 µg/mL), chloramphenicol (30 µg/
mL), or trimethoprim-sulfamethoxazole (40/200 µg/mL).
Under the above conditions, the detection sensitivity of the
mating assay was >1 × 108 transconjugants/recipients.
Results
Antimicrobial Drug–Resistance Rates
Overall, high resistance rates were observed for ampi-
cillin (95%), trimethoprim-sulfamethoxazole (94%), tetra-
cycline (93%), streptomycin (82%), and chloramphenicol
(70%). Lower resistance rates were observed for nalidixic
acid (35%), kanamycin (28%), gentamicin (21%), and
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amikacin was uncommon (<0.5%) (Table 1). For first-line
oral antimicrobial agents such as ampicillin, tetracycline,
and trimethoprim-sulfamethoxazole, resistant strains were
present as the dominant flora in >80% of carriers (Table 1).
Resistance rates for ampicillin, trimethoprim-sul-
famethoxazole, kanamycin, and streptomycin were signif-
icantly higher in Bolivia than in Peru (p<0.001), whereas
ciprofloxacin resistance rates were significantly higher in
Peru than in Bolivia (p<0.001) (Table 1). Differences in
the resistance rates were also observed within each coun-
try. In Bolivia, higher overall resistance rates were found
in Camiri than in Villa Montes (p<0.001) for chloram-
phenicol, streptomycin, gentamicin, nalidixic acid, and
ciprofloxacin (Table 1). In Peru, higher overall resistance
rates were found in Moyobamba than in Yurimaguas. The
most significant differences (p<0.001) were noted for
streptomycin, nalidixic acid, and ciprofloxacin (Table 1).
Significantly higher (p<0.05) resistant rates were
observed in boys, with some agents, and in some settings
(ampicillin in both Peruvian cities, trimethoprim-
sulfamethoxazole in Moyobamba, and chloramphenicol,
kanamycin, and gentamicin in Camiri). Analysis by age
showed that, with all agents (ceftriaxone and amikacin
were not considered in this analysis because of the low
numbers of resistant isolates), resistance rates were notably
higher in the youngest age group, and an overall decreasing
trend by age was observed (Figure 2). With some agents
(kanamycin, gentamicin, and the quinolones), the decreas-
ing trend was essentially limited to the younger age groups;
with other agents (ampicillin, tetracycline, trimethoprim-
sulfamethoxazole, and chloramphenicol); this phenomenon
was more evident in the older age groups.
Combinations of Antimicrobial Drug–resistance 
Traits in Healthy Children
Of the 3,174 children evaluated in the study, only 84
(2.7%) carried an E. coli fecal population susceptible to all
the antimicrobial agents tested, while 46 (1.5%), 73
(2.3%), 187 (5.9%), 537 (17%), 808 (26%), 624 (20%),
and 816 (26%) had an E. coli population resistant to 1, 2,
3, 4, 5, 6, or >6 antimicrobial agents. No significant differ-
ences in this distribution were observed between the 2
countries. Of the 156 different combinations of resistance
observed, 2 were most prevalent: 1) the pattern with 4
resistances, (ampicillin, tetracycline, trimethoprim-sul-
famethoxazole, and streptomycin) in 361 (11.5%) children
and 2) the pattern with 5 resistances, (ampicillin, tetracy-
cline, trimethoprim-sulfamethoxazole, streptomycin, and
chloramphenicol) in 567 (18%) children.
Patterns of Resistance Phenotypes of E. coli Isolates
Frequency and patterns of resistance phenotypes were
determined on a random sample of 1,080 nonreplicate
resistant E. coli isolates with 8 antimicrobial agents repre-
sentative of 6 different classes (ampicillin for β-lactams,
tetracycline for tetracyclines, chloramphenicol for pheni-
cols, trimethoprim-sulfamethoxazole for folate inhibitors,
kanamycin and gentamicin for aminoglycosides, and
nalidixic acid and ciprofloxacin for quinolones). Only a
few isolates were resistant to a single drug (9%) (Figure 3).
Isolates showing resistance to 3 different drugs were the
most prevalent (30%), followed by those showing resist-
ance to 4 (22%) and 2 (20%) drugs, respectively. Seven
isolates (<1%) showed resistance to all tested drugs
(Figure 3). An MDR phenotype was common (90% of iso-
lates). Resistance patterns were quite variable. Of 97 dif-
ferent patterns observed, some were highly prevalent. The
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prim-sulfamethoxazole was the most prevalent, followed
by that including ampicillin, tetracycline, trimethoprim-
sulfamethoxazole, and chloramphenicol, as well as that
including ampicillin and trimethoprim-sulfamethoxazole
alone (22%, 15%, and 10% of the tested isolates, respec-
tively) (Figure 3).
Acquired Resistance Genes and Transferability 
of Resistance Traits
The prevalence of several acquired resistance genes
(blaTEM for ampicillin resistance; tet(A)–(D) for tetracy-
cline resistance; dfrA8 for trimethoprim resistance; sul1
and  sul2 for sulfonamide resistance; catI for chloram-
phenicol resistance) and class 1 integrons was investigated
in 78 isolates randomly selected from representatives of
the 2 most prevalent MDR phenotypes (ampicillin/tetracy-
cline/trimethoprim-sulfamethoxazole, n = 45; ampicillin/
tetracycline/trimethoprim-sulfamethoxazole/chloram-
phenicol, n = 33). In most cases the resistance phenotype
could be accounted for by a combination of the above
resistance genes, and some of them appeared to be highly
prevalent (Table 2). The presence of the intI1 integrase
gene (associated with class 1 integrons) was detected in
35% of MDR isolates.
These 78 isolates were also tested for transferability of
resistance traits in conjugation experiments. Overall, the
transfer of at least 1 resistant trait was observed in 37 cases
(47%). Transfer rates for each resistance trait were as fol-
lows: ampicillin 46%, tetracycline 40%, trimethoprim-
sulfamethoxazole 41%, and chloramphenicol 27%. Co-
transfer of all the resistance traits was observed in 26 of the
37 cases that gave positive results in the conjugation
experiments. Molecular analysis of the transconjugants
showed that, in all the cases, the resistance phenotype
could be accounted for by the acquisition of resistance
genes detected in the respective donors. Conjugative trans-
fer of class 1 integrons was observed in 10 (37%) of the 27
intI1–positive isolates.
Discussion
Similar to pathogenic bacteria, commensals are
exposed to the selective pressure of antimicrobial agents,
and commensal E. coli have often been used as an indica-
tor of the dissemination of acquired resistance genes
(7,8,11–13,15,27). To our knowledge, this study is the first
to address the status of antimicrobial drug resistance in
commensal E. coli in a large population of preschool-age
children from urban settings of low-resource countries.
Results showed a high prevalence (70%–95%) of healthy
carriers of E. coli resistant to a number of older antimicro-
bial agents (ampicillin, tetracycline, trimethoprim-sul-
famethoxazole, chloramphenicol, and streptomycin). For
these drugs, the small differences observed among locali-
ties, although sometimes statistically significant, are prob-
ably of limited clinical and epidemiologic relevance and
presumably attributable to the large number of antimicro-
bial drug–resistant E. coli carriers. Arelatively high preva-
lence (18%–35%) of carriers of E. coli resistant to other
agents (kanamycin, gentamicin, nalidixic acid, and
ciprofloxacin) was also observed, while the carriage of E.
coli resistant to expanded-spectrum cephalosporins and
amikacin was uncommon (<0.5%). Ranking patterns of
resistance rates were similar overall in each of the 4 stud-
ied areas, which suggests a common scenario in urban
Drug-resistant E. coli, Peru and Bolivia
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Figure 2. Total prevalence, by age group, of fecal carriage of
antimicrobial drug–resistant Escherichia coli among 3,174 children
in 4 urban areas of Bolivia and Peru. Ceftriaxone and amikacin
were not considered in these analyses because their resistance
rates were too low. 
Figure 3. Frequency of resistance phenotypes in 1,080 randomly
selected antimicrobial drug–resistant Escherichia coli isolates from
4 urban areas of Bolivia and Peru. Black bars indicate the most
frequent resistance and multidrug-resistance phenotype within
each category: 1R, TET; 2R, AMP-SXT; 3R, AMP-TET-SXT; 4R,
AMP-TET-SXT-CHL; 5R, AMP-TET-SXT-CHL-KAN; 6R, AMP-
TET-SXT-CHL-NAL-CIP; 7R, AMP-TET-SXT-CHL-GEN-NAL-CIP;
8R, AMP-TET-SXT-CHL-KAN-GEN-NAL-CIP. AMP, ampicillin;
TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; CHL, chlo-
ramphenicol; KAN, kanamycin; GEN, gentamicin; NAL, nalidixic
acid; CIP, ciprofloxacin. areas of these 2 Latin American countries. This view is
further supported by data recently published for adults
from Lima (Peru), where similar resistance rates were
reported (12). 
Our findings were in substantial agreement with previ-
ous reports of high resistance rates in commensals of study
participants from low-resource settings (7,8,11–13,15,28).
Comparative analysis with previous data available for 1
studied setting (Camiri, Bolivia) surveyed 10 years earlier
(7) indicated a significant increase in the resistance rates to
gentamicin and nalidixic acid and the de novo appearance
of resistance to ciprofloxacin. 
One aspect that was not previously reported among pre-
school children was the age-related differences in resist-
ance rates; rates were significantly higher in the younger
age groups. This phenomenon could reflect a larger use of
antimicrobial drugs in younger children. However, this
explanation cannot be the case for quinolones, which are
not prescribed in this age group. Another influencing fac-
tor could be dietary changes related to weaning. In fact, a
diet high in milk that contains abundant lactoferrin, which
chelates dietary iron, has been hypothesized to favor the
presence of strains expressing iron-uptake systems (such
as aerobactin or enterobactin), which are often encoded by
plasmids that also carry resistance genes (29). However,
further investigation will be necessary to clarify the mech-
anism responsible for this phenomenon.
Multiple resistance traits in the commensal E. coli
microbiota were apparently the rule, as they were detected
in most study participants. The simultaneous presence of
multiple strains expressing different resistance phenotypes
and single strains expressing MDR phenotypes could con-
tribute to this phenomenon. Although the relative contribu-
tion of the 2 mechanisms was not specifically investigated,
the high prevalence of strains expressing MDR phenotypes
probably provides a major contribution. Some MDR pat-
terns (e.g., ampicillin/tetracycline/trimethoprim-sulfa-
methoxazole, ampicillin/tetracycline/ trimethoprim-sulfa-
methoxazole/chloramphenicol) were  common and could
be accounted for by a number of known acquired resist-
ance genes. Resistance traits could be transferred by con-
jugation, often en bloc, suggesting a linkage of the
corresponding resistance genes in self-transferable or
mobilizable plasmids.
In conclusion, this study underscores the magnitude of
the problem of antimicrobial drug resistance in low-
resource settings and the urgent need for surveillance and
control of this phenomenon. Inexpensive, sensitive, and
simple methods to monitor antimicrobial drug resistance in
commensal bacteria could be valuable tools for large-scale
surveillance studies and to improve the efficacy of
resistance control interventions. The direct plating method
used in this study, which had previously shown high sensi-
tivity and specificity in detecting resistant E. coli (19), was
confirmed to be a valid tool to conduct such a large-scale
survey.
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